Anne Mobley Butler, PhD

Assistant Professor of Medicine

Dr. Butler is a pharmacoepidemiologist with broad research interests in non-experimental studies, real-world data, comparative effectiveness research, and epidemiologic methods. Her research involves the application of epidemiologic study designs and analytic methods to highly detailed, clinical and administrative data captured on patients as part of routine clinical care. Her substantive work focuses on the treatment and prevention of common infections, including antibiotic and vaccine utilization, effectiveness, safety, and related outcomes. She also applies and develops epidemiological methods to identify and account for common sources of biases in non-experimental studies that use administrative data. Given that various patient populations are rarely included in clinical trials, real-world evidence generated from these studies are useful to inform decisions related to clinical practice, health policy, and quality improvement interventions. Dr. Butler has a secondary appointment in the Division of Public Health Sciences at Washington University School of Medicine.

Additional Titles
  • Scholar – Institute for Public Health
  • BS – Neuroscience & Behavioral Biology: Emory University, Atlanta GA (2003)
  • MS – Epidemiology: Harvard School of Public Health (2006)
  • PhD – Epidemiology: Gillings School of Global Public Health, University of North Carolina at Chapel Hill (2014)
  • Postdoctoral Fellowship – Epidemiology: Gillings School of Global Public Health, University of North Carolina at Chapel Hill (2015-2017)
Selected Publications
  1. Estimating the effectiveness of rotavirus vaccine schedules. Butler AM, Breskin A, Sahrmann JM, Brookhart MA. Epidemiology. 2021 Jul 1;32(4):598-606. doi: 10.1097/EDE.0000000000001363.
  2. Risk of antibiotic treatment failure in premenopausal women with uncomplicated urinary tract infection. Butler AM, Durkin MJ, Keller MR, Ma Y, Dharnidharka VR, Powderly WG, Olsen MA. Pharmacoepidemiology and Drug Safety. 2021 Mar 30. doi: 10.1002/pds.5237. Online ahead of print.
  3. Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease. Layton JB, McGrath LJ, Sahrmann JM, Ma Y, Dharnidharka VR, O’Neil C, Weber DJ, Butler AMVaccine. 2020 Jul 14;38(33):5178-5186. doi: 10.1016/j.vaccine.2020.06.020. Epub 2020 Jun 19.
  4. Informative censoring by health plan disenrollment among commercially insured adults. Butler AM, Todd JV, Sahrmann JM, Lesko CR, Brookhart MA. Pharmacoepidemiology and Drug Safety. 2019 May;28(5):640-648. doi: 10.1002/pds.4750. Epub 2019 Feb 20.
  5. Assessing residual bias in estimating influenza vaccine effectiveness: comparison of high-dose versus standard-dose vaccines. Butler AM, Layton JB, Krueger WS, Kshirsagar AV, McGrath LJ. Medical Care. 2018 Nov 12. doi: 10.1097/MLR.0000000000001018. [Epub ahead of print]

View More Publications